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Abstract
Abnormal microRNA (miRNA) expression has been linked to the development and progression of several human cancers,
and such dysregulation can result from aberrant DNA methylation. While a small number of miRNAs is known to be
regulated by DNA methylation, we postulated that such epigenetic regulation is more prevalent. By combining MBD-
isolated Genome Sequencing (MiGS) to evaluate genome-wide DNA methylation patterns and microarray analysis to
determine miRNA expression levels, we systematically searched for candidate miRNAs regulated by DNA methylation in
colorectal cancer cell lines. We found 64 miRNAs to be robustly methylated in HCT116 cells; eighteen of them were located
in imprinting regions or already reported to be regulated by DNA methylation. For the remaining 46 miRNAs, expression
levels of 18 were consistent with their DNA methylation status. Finally, 8 miRNAs were up-regulated by 5-aza-29-
deoxycytidine treatment and identified to be novel miRNAs regulated by DNA methylation. Moreover, we demonstrated the
functional relevance of these epigenetically silenced miRNAs by ectopically expressing select candidates, which resulted in
inhibition of growth and migration of cancer cells. In addition to reporting these findings, our study also provides a reliable,
systematic strategy to identify DNA methylation-regulated miRNAs by combining DNA methylation profiles and expression
data.
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Introduction
MicroRNAs (miRNAs)aresmall,non-coding RNAs that regulate
gene expression and play pivotal roles in normal cellular processes
including proliferation, differentiation, and apoptosis [1]. Both
aberrantexpressionand silencingofmiRNAshavebeenobservedin
human cancers, suggesting potential oncogenic and tumor suppres-
sor functions for these miRNAs [2,3]. The biogenesis of miRNAs
involves transcription of a long primary transcript (pri-miRNA) by
RNA polymerase II [4], cleavage into an intermediate product (pre-
miRNA) by Drosha [5], and final processing into the mature
miRNA by Dicer [6]. Each step of the process is highly regulated,
and dysregulation at any level can result in inappropriate miRNA
functions. Of particular interest to our study is miRNA transcrip-
tional regulation by DNA methylation. Generally, gene promoter
DNA methylation is negatively correlated to gene expression and
can account for aberrant tumor suppressor gene silencing in a
variety of human cancers [7]. Similar to these POLR2A transcribed
protein coding genes, miRNA transcription may also be silenced by
promoter DNA methylation.
Epigenetically silenced miRNAs have been discovered in
cancers based on differential expression between normal tissues
and tumors or between baseline and DNA demethylated cancer
cells. For instance, Bandres et al. first identified 23 miRNAs that
are down-regulated in primary colorectal cancers compared with
matched normal colorectal epithelium and subsequently discov-
ered that miR-129-2, miR-9-1, and miR-137 are silenced by DNA
methylation in cancer [8]. Toyota et al. treated HCT116 colorectal
cancer cells with the demethylating agent, 5-aza-29-deoxycytidine
(5-aza-dC), and compared miRNA expression profiles between the
treated and the untreated cells to identify silencing of miR-34b/c
by promoter DNA hypermethylation [9]. Furthermore, Lujambio
et al. compared the miRNA expression profile of wildtype
HCT116 cells with that of its demethylated isogenic derivative,
DNA methyltransferase 21 and 23b Double Knockout (DKO)
cells, and found 18 miRNAs up-regulated in DKO cells [10].
Subsequently, they confirmed that DNA methylation is responsi-
ble for the silencing of miR-124a in colon cancer.
A literature search using MEDLINE revealed that 16 miRNAs
are known to be epigenetically silenced by DNA methylation
[8,9,10,11,12,13,14,15,16,17]. DNA methylation refers to the
covalent addition of a methyl group to the 5-position of cytosines,
usually in a CpG dinucleotide context in mammalian differenti-
ated cells [18]. Genomic regions with a high density of CpGs are
termed CpG islands and are often the sites of regulatory DNA
methylation. Considering that 16% of the annotated human
miRNAs are located within 1000 bp of a CpG island [19], we
surmise that epigenetic regulation of miRNAs might be more
common than reported thus far. Previous studies relied on
differential expression of miRNAs to identify candidates for
subsequent epigenetic evaluation. This approach introduces bias
that limits the number of epigenetically regulated miRNAs that
can be discovered. For example, tissue-specific miRNAs that are
regulated by DNA methylation may be equivalently methylated in
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expression between normal and cancerous specimens. Further-
more, miRNAs with low expression levels cannot be reliably
identified because the differences in expression between normal
and cancer or between baseline and demethylated conditions will
likely fall below conventional cutoffs (between 2 and 1.5 fold).
Finally, residual methylation persists in both pharmacologically
and genetically demethylated cells [20]. Such methylation may be
critical in maintaining cell viability, potentially through persistent
repression of key miRNAs. This would result in such miRNAs not
being identified through expression-based strategies.
To overcome the discovery bias introduced by expression-based
identification strategy, we directly utilized global DNA methyla-
tion patterns to identify miRNAs regulated by DNA methylation
in HCT116 and DKO colon cancer cells. We have previously
mapped genome-wide DNA methylation in these cell lines using
methyl CpG binding domain (MBD)-isolated Genome Sequencing
(MiGS) [21]. We first identified miRNAs with proximal DNA
methylation as candidates. We then cross-referenced the list of
candidates with miRNA expression data as supporting evidence.
Using this approach, we successfully identified both known and
novel DNA methylation-regulated miRNAs. Here we provide a
more comprehensive catalogue of epigenetically regulated miR-
NAs in colon cancer cells, demonstrating that epigenetic
regulation of miRNAs is prevalent in these cancer cell lines.
Furthermore, functional studies of select miRNAs provide
biological relevance for such epigenetic regulation in the context
of colon cancer.
Results
Candidate miRNAs regulated by DNA methylation were
identified by proximal genomic DNA methylation and
supporting expression data
We previously used MiGS to construct genome-wide DNA
methylation profiles for the HCT116 cell line and its demethylated
isogenic cell line, DKO [21]. DKO cells are HCT116 cells deleted
for DNA methyltransferase 21 and 23b and retain ,5%
genomic DNA methylation [20]. DNA methylated fractions of
the genome were isolated by incubation with recombinant MBD
proteins, sequenced on an Illumina GAII sequencer, and mapped
back to the reference genome to generate individual methylome
profiles. To identify DNA methylation-regulated miRNAs, we
searched for miRNAs with evidence of DNA methylation within
500 bp of their annotated positions in HCT116 and DKO cells.
Using this approach, we identified 64 candidate miRNAs for
subsequent analysis (Figure 1).
Of the 64 candidate miRNAs, 13 have been reported to be
regulated by DNA methylation (Table S1). Another 5 belong to a
large miRNA cluster located in the human DLK1–GTL2
imprinted domain at 14q32 and are silenced on the paternal
chromosome by DNA methylation [22]. Therefore, we focused on
the remaining 46 miRNAs that have not been reported to be
regulated by DNA methylation for detailed validation. First, we
randomly selected 6 miRNAs for bisulfite sequencing analysis to
verify the DNA methylation status detected by MiGS (Figure 2
and Figure S1). The bisulfite sequencing data corroborated the
MiGS data at all 6 loci.
Next, we reasoned that loss of DNA methylation in DKO cells
when compared to HCT116 cells should result in increased
expression of the candidate miRNAs while retention of DNA
methylation should correlate to persistent silencing of the
candidate miRNAs. Therefore, we examined the expression
microarray data for the 46 candidates in HCT116 and DKO
cells (Table S2). Using 1.5-fold change as our threshold, we
identified 18 miRNAs as having consistent expression data with
their DNA methylation status in HCT116 and DKO cells (Table
S1). We performed miRNA-specific quantitative real-time RT–
PCR (miR-qRT–PCR) analysis for 6 select miRNAs to verify the
expression data determined by the microarray (Figure S2). The
miR-qRT-PCR results confirmed the microarray data for the 6
miRNAs, which included both known and candidate DNA
methylation-regulated miRNAs. Therefore, based on empirical
genomic DNA methylation and supporting microarray expression
data, we identified 18 novel candidate miRNAs that may be
transcriptionally regulated by DNA methylation.
Candidate miRNAs re-express after 5-aza-29-
deoxycytidine treatment
To validate that the candidate miRNAs were indeed regulated
by DNA methylation, we treated HCT116, RKO, and DLD1
colon cancer cells with the demethylating agent 5-aza-29-
deoxycytidine (5-aza-dC) to determine whether these miRNAs
are re-expressed after 5-aza-dC treatment. As DNA methylation
regulates gene expression at the transcriptional level, we assayed
for the expression of the primary miRNAs (Pri-miRNA) by real
time RT-PCR [23]. included Pri-miR-193a, 29-3, and 2375,
which were known to be transcriptionally regulated by DNA
methylation in HCT116 cells [8], as positive controls and Pri-miR-
1224, which was demethylated but remained silenced in DKO
cells in this study, as a negative control. We tested 17 out of the 18
novel candidates because none of the primers designed for miR-
1234 yielded successful PCR products. In HCT116 cells, we found
11 out of 17 miRNAs to be significantly up-regulated after 5-aza-
dC treatment (Figure 3A). We further independently confirmed all
11 candidates in RKO cells (Figure 3B) and 10 out of the 11
candidates in DLD1 cells (Figure 3C). To verify that the up-
regulation of these miRNAs was consequent to DNA demethyl-
ation after 5-aza-dC treatment, we assessed changes in DNA
methylation status in the proximal regions of miR-941-1/3, miR-
1237 and miR-1247 by bisulfite genomic sequencing (Figure 2).
Demethylation was observed at these loci in HCT116 cells treated
with 5-aza-dC, supporting that the re-expression observed was due
to DNA demethylation.
Finally, intronic miRNAs can be co-transcribed from host gene
promoters and therefore, are not independently regulated at the
transcriptional level [24,25]. Hence, to fully understand the
significance of the DNA methylation we observed for our 10
candidate miRNAs, we examined the genomic contexts of the 10
candidates more closely (Table 1). miR-1247, miR-1826, and
miR-219-2 are located in intergenic regions and therefore, are
unlikely to be co-regulated by a host gene promoter. The
remaining 7 candidates are located in introns of RefSeq or EST
transcripts and were studied further. Based on the genome-wide
DNA methylation profiles, none of the putative host genes, except
for the non-coding RNA ANKRD30BL, have significant DNA
methylation at their promoters (Table 1 and Figure S3), suggesting
that these putative host genes are not regulated by promoter DNA
methylation.
Nonetheless, we postulated that if the putative host gene
transcription dictates the expression of the embedded candidate
miRNAs, we should detect increased host gene expression after 5-
aza-dC treatment in HCT116, RKO, and DLD1 cells. Such
increases in the host gene expression would correspond to the
increases observed for the embedded miRNAs in these same cells
after 5-aza-dC treatment. Conversely, if the putative host genes do
not respond to 5-aza-dC treatment in the same manner as the
embedded miRNAs, the miRNAs are likely transcribed indepen-
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methylation we discovered near the miRNAs would be most
meaningful in their transcriptional regulation. Based on qRT-PCR
results, we determined that miR-1237, miR-602, miR-941-1, miR-
941-3, and miR-663b are transcriptionally independent from their
respective putative host genes (Figure 4). The expression of
ANKRD30BL, the putative host gene for miR-663b, was not
detectable before or after 5-aza-dC experiments and therefore, not
plotted in Figure 4. For miR-24-1 and miR-27b, the data is less
conclusive, and we could not rule out that these two mi-RNAs can
be co-synthesized with the host gene, C9orf3 [26]. Altogether, we
identified and confirmed at least 8 novel miRNAs that are
transcriptionally regulated by DNA methylation.
miR-941 and miR-1247 suppress cell growth and
migration in colon cancer cells
We proceeded to test the biological functions of these
epigenetically regulated miRNAs to gain insights into the
relevance of their DNA methylation in colon cancer cells. To
determine if expression of these epigenetically silenced miRNAs
would affect cancer cell growth and migration, we transfected
HCT116 cells with miRNA mimics of miR-941 (the mature form
of miR-941-1 and -3), miR-1237, miR-1247, and a non-coding
negative control (AllStars Neg.).
First, we performed growth curve analysis (Figure 5A) and
MTT assay (Figure 5B) to assess cell growth and metabolic fitness.
We found that ectopic expression of miR-1247 resulted in a
significant decrease in HCT116 cell growth and metabolic activity
as measured by the two assays respectively. BrdU incorporation
assay independently verified that the decreased growth and
metabolism is likely a consequence of decreased proliferation in
these cells (Figure 5C). We observed a similar decrease in cell
proliferation and metabolic function in DLD1 colon cancer cells
transfected with miR-1247 mimic (Figure S4A and B). Conversely,
in DKO cells, where miR-1247 is already demethylated and re-
expressed, transfection with additional miR-1247 mimics did not
have any effects on cell growth and metabolism (Figure S5A and
B). These observations suggested that miR-1247 may be tumor-
suppressive in colon cancer and its epigenetic silencing is therefore
beneficial for cancer growth.
Furthermore, computationally predicted targets of miR-941 and
miR-1247 included several genes involved in cell migration and
invasion. For example, ADAM metallopeptidase domain 15
(ADAM15) is a predicted target of miR-1247 and encodes a
transmembrane glycoprotein important for cell adhesion [27]. We
postulated that down-regulation of these predicted targets by
ectopic expression of miR-941 and miR-1247 would negatively
impact cell migration. Hence, we tested the effects of ectopic
expression of miR-941, miR-1237, and miR-1247 on cell mobility
in HCT116 cells. In wound-healing assays, HCT116 cells
transfected with miR-941 and miR-1247 mimics were significantly
impaired in their ability to repopulate wounded areas when
compared to mock, negative control, or miR-1237 transfected cells
(Figure 5D). These observations were further confirmed using the
Figure 1. Overview of the screening approach performed in this study.
doi:10.1371/journal.pone.0020628.g001
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PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e20628Figure 2. Representative bisulfite sequencing of candidate miRNAs. Bisulfite sequencing was carried out for (A) miR-941, (B) miR-1237, and
(C) miR-1247 in parental HCT116 cells, HCT116 cells treated with 5 mM 5-aza-dC for 48 hr, and DKO cells. The UCSC genome browser screen capture
shows the DNA methylation signal in each sample. The rectangles mark the regions validated by bisulfite sequencing. Each circle represents a CpG
dinucleotide. Black circles represent methylated cytosines while white circles represent unmethylated cytosines.
doi:10.1371/journal.pone.0020628.g002
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PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e20628Figure 3. Expression analysis of candidate miRNAs after 5-aza-dC treatment. Real-time RT-PCR analysis was carried out to assess candidate
primary miRNAs (Pri-miRNAs) levels in (A) HCT116, (B) RKO, and (C) DLD1 cells before and after treatment with 5 mM 5-aza-dC for 48 hr. miR-1224 was
included as a negative control. miR-193a, miR-375, and miR-9-3 were included as positive controls. * indicates significant increase in Pri-miRNA
expression after 5-aza-dC treatment (p,0.05). Expressions of miRNAs were internally normalized to the expression levels of GAPDH, and normalized
expression for each miRNA before 5-aza-dC treatments was set to 1.
doi:10.1371/journal.pone.0020628.g003
Study of Epigenetically Regulated MicroRNAs
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e20628transwell migration assay (Figure 5E). Finally, similar suppressive
effects on cell migration were independently observed in DLD1
cells (Figure S4C) and DKO cells (Figure S5C) transfected with
miR-941 and miR-1247 mimics. Taken together, these observa-
tions suggest that the epigenetic silencing of miR-941 and miR-
1247 may facilitate colon cancer cell migration and invasion.
Discussion
MicroRNAs are important regulatory molecules that modulate
gene expression in both developmental and disease processes.
Their regulation is, therefore, a critical component in understand-
ing each biological context. Genomic DNA methylation has been
shown to regulate the transcription of a handful of miRNAs in
cancer. These previous studies aimed at identifying DNA
methylation-regulated miRNAs relied on screening for differen-
tially expressed miRNAs from cancer and normal comparisons or
re-expression of miRNAs in DNA demethylated conditions. An
expression-based approach introduces a discovery bias against
equivalently methylated, therefore equivalently silenced, miRNAs
in the comparison groups. This type of epigenetically regulated
miRNA could still be important for cancer development. For
instance, equivalently silenced miRNAs in normal and cancer may
be significant for cancer in a tissue-specific manner. Furthermore,
residual DNA methylation in induced demethylation conditions
could sustain silencing of critical miRNAs, resulting in lack of
detectable differential expression and failure to identify such
epigenetically regulated miRNAs. Finally, miRNAs with marginal
differential expression below typical thresholds would also be
missed when the screening is based solely on differential
expression.
To overcome the above biases and more comprehensively
identify DNA methylation-regulated miRNAs in colon cancer, we
screened for candidate miRNAs based on empirical evidence of
genomic DNA methylation in HCT116 and DKO colon cancer
cells. We systematically searched the DNA methylome maps
generated by MiGS in these cells for miRNAs located within
500bp of DNA methylation signals. We found 64 candidates,
including 5 known imprinted miRNAs, 13 known DNA
methylation-regulated miRNAs, and 46 novel candidates. Subse-
quently, we confirmed that 8 novel candidates were indeed
regulated by DNA methylation in HCT116, DKO, RKO, and
DLD1 colon cancer cells. Together with the detection of known
DNA-methylation regulated miRNAs, our study identified a total
of 26 epigenetically regulated miRNAs, demonstrating that our
approach is effective and efficient.
It is important to note that we may still be missing DNA
methylation-regulated miRNAs derived from long primary
transcripts. Previous studies focused on miRNAs with their stem-
loop sequences embedded in or near CpG islands, and our current
study focused on miRNAs with DNA methylation proximal to the
stem-loop sequences. While these similar strategies allow for
systematic screening, they likely underestimate the total number of
miRNAs regulated by DNA methylation because transcription
initiation for the primary miRNAs can be far upstream from the
stem-loop sequence. For example, the primary transcript of miR-
21 is 3433 nucleotide-long while the mature miR-21 is encoded by
Table 1. Genomic context of candidate miRNAs.
miRNA Genomic context
Putative host gene promoter
methylation*
Host gene expression after 5-aza-dC
treatment
hsa-miR-1237 RPS6KA4 intron No methylation No change
hsa-miR-1247 Intergenic N/A N/A
hsa-miR-1826 Intergenic N/A N/A
hsa-miR-219-2 Intergenic N/A N/A
hsa-miR-24-1 C9orf3 intron No methylation Inconsistent increase in expression
hsa-miR-27b C9orf3 intron No methylation Inconsistent increase in expression
hsa-miR-602 AB058779 intron No methylation No change
hsa-miR-663b ANKRD30BL intron Methylation in HCT116 Not expressed
hsa-miR-941-1 DNAJC5 intron No methylation No change
hsa-miR-941-3 DNAJC5 intron No methylation No change
Note: * Putative host gene promoter is defined as 61000 bp from the annotated transcription start sites.
doi:10.1371/journal.pone.0020628.t001
Figure 4. Expression analysis of putative host genes after
5-aza-dC treatment. Real-time RT-PCR analysis was carried out to
assess putative host gene expression in response to 5-aza-dC
treatments in HCT116 (blue), RKO (dark pink), and DLD1 (yellow). The
changes in embedded miRNA expression were also plotted for side-by-
side comparisons. All expressions were internally normalized to the
expression levels of GAPDH, and normalized expression for each host
gene and miRNA before 5-aza-dC treatments was set to 1.
doi:10.1371/journal.pone.0020628.g004
Study of Epigenetically Regulated MicroRNAs
PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e20628Study of Epigenetically Regulated MicroRNAs
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20628residues +2445 to +2516 in HeLa cells [28]. Recently, Chim et al.
reported that miR-34a was regulated by promoter CpG island
DNA methylation located .30 kb upstream from the mature
miR-34a [29]. Therefore, more miRNAs may be regulated by
promoter DNA methylation but will not be readily identified using
a systematic approach that relies on the current genome
annotation.
We further examined the biological relevance of the epigenetic
silencing of the newly identified DNA methylation-regulated
miRNAs. We focused on two important aspects of cancer
development, growth and migration, and selected miR-941,
miR-1237, and miR-1247 for functional studies. Ectopic expres-
sion of miR-1247 significantly reduced cancer cell proliferation
and migration in HCT116 and DLD1 cells, suggesting that miR-
1247 may function as a tumor suppressor. These observations are
consistent with the functions of several predicted targets of miR-
1247 (http://www.microrna.org). For example, Citron (CIT), a
serine/threonine kinase, is present at the cleavage furrow and
midbody during cytokinesis and is essential for cellular abscission
[30,31]. CIT also regulates the G2/M transition in rat hepatocytes
[32], and knocking down CIT inhibited the proliferation of
hepatocellular carcinoma cells [33]. Another potential target for
miR-1247 is FosB, which dimerizes with Jun protein to activate
transcription of proteases involved in tumor migration and
invasion [34]. Finally, the transmembrane glycoprotein, AD-
AM15, might also be targeted by miR-1247, to facilitate prostate
cancer metastasis [35]. These computationally predicted targets
will need to be empirically validated in the future.
Interestingly, in DKO cells, where miR-1247 is demethylated
and expressed at higher levels than HCT116 cells, additional
exposure to miR-1247 mimics did not result in decreases of cell
growth but caused impaired migration. The discrepancies between
the phenotypes of ectopic miR-1247 expression in HCT116,
DLD1, and DKO cells may reflect the different concentrations at
which distinct cellular functions are modulated by miR-1247.
Alternatively, it may be due to the presence of different targets for
miR-1247 in HCT116 and DKO cells. These two possibilities will
require additional studies to clarify.
While differentially methylated and expressed miRNAs are
important for cancer development, we proposed that residual
DNA methylation in demethylated conditions, such as in DKO
cells, may also be critical. Our functional study of miR-941
substantiated this hypothesis. We found that over-expression of
miR-941 was able to significantly inhibit cell migration in both
HCT116 and DKO cells and additionally in DLD1 cells. This
result is reasonable considering several high priority predicted
targets of miR-941 are related to cell migration. For instance,
matrix metallopeptidase 24 (MMP24) is a predicted target for
miR-941, and it facilitates tissue remodeling and cell migration in
endometrium from endometriosis patients [36]. Similar type of
DNA methylation-regulated miRNAs would be missed by
previous expression-based approach but could be readily captured
by our study design. Six out of the 8 novel epigenetically regulated
miRNAs identified in our study retained proximal DNA
methylation in DKO cells, where ,5% genomic DNA methyl-
ation is left compared to its parental HCT116 cells.
In summary, our approach to discover DNA methylation-
regulated miRNAs yielded a number of previously undiscovered
candidates. We have shown through ectopic expression and
functional assays that at least two of these miRNAs may be
particularly important in tumor progression. Our method is a
useful complement to the traditional approach of using an
expression-based scheme to identify novel miRNAs silenced by
DNA methylation.
Materials and Methods
Cell culture and drug treatment
Colorectal cancer cell lines HCT116, DLD1, RKO and DKO
cells [25] were cultured in McCoy’s 5A media (Invitrogen, San
Diego, CA) containing 10% fetal bovine serum (Gibco, Grand
Island, NY) at 37uCi n5 %C O 2 atmosphere. Cells were harvested
by scraping, and cell pellets were rinsed twice with PBS (Gibco,
Grand island, NY). Total RNA was isolated using Trizol
(Invitrogen, San Diego, CA) extraction according to manufactur-
er’s instructions. Total RNA was also treated with DNase I
(Roche, Indianapolis, IN) to remove trace amounts of residual
genomic DNA. Genomic DNA was extracted from cell pellets by
incubating the pellets in solutions containing 0.5 mg/mL Protein-
ase K, 2% SDS, and 20 mM Tris-HCl overnight at 55
oC with
shaking followed by phenol-chloroform extraction and ethanol
precipitation. For 5-aza-29-deoxycytidine (5-aza-dC) treatments,
cells were seeded at 5610
5 cells per 100-mm dish 24 hr prior to
the addition of 5-aza-dC (Sigma, St Louis, MO). Cells were
treated with 5 mM 5-aza-dC for 48 hr before harvesting.
MBD-isolated Genome Sequencing data analysis
Genome-wide DNA methylation data for HCT116 and DKO
cells were previously obtained by performing MBD-isolated
Genome Sequencing (MiGS) [21]. The raw sequencing reads
can be downloaded from the NCBI Short Read Archive
(SRA#SRP001414). The minimum number of sequencing reads
indicating significant DNA methylation signals were determined as
previously described. Annotated miRNAs (Hg18, NCBI Build
36.1) located within 500 bp of significant DNA methylation were
identified as candidates for subsequent analyses.
miRNA microarray analysis
Microarray-based miRNA expression profiling was performed
using the Illumina human MicroRNA expression profiling V2
panel according to manufacturer’s instructions. The human v2
miRNA panel contains 1,146 assays, for detection of ,97% of the
miRNAs described in the miRBase database (Sanger miRBase,
v9.1, February 2007 release). Data processing was performed in
GenomeStudio v2009.1 (Illumina, San Diego, CA). Triplicate
experiments were performed for each cell line. Data from each
Figure 5. Functional analysis of miR-941, miR-1237, and miR-1247 in HCT116 cells. (A) Growth curves and (B) MTT assays of mock
transfected HCT116 cells and HCT116 cells transfected with non-coding negative control miRNA (AllStars Neg.), miR-941, miR-1237, or miR-1247
mimics. (C) BrdU incorporation assay of mock transfected HCT116 cells and HCT116 cells transfected with non-coding negative control miRNA
(AllStars Neg.), miR-941, or miR-1247. A representative field for each experimental condition is shown. The bar graph represents the average
percentage (%) of BrdU positive cells. (D) Wound-healing assay for mock transfected HCT116 cells and cells transfected with negative control (AllStars
Neg.), miR-941, miR-1237, or miR-1247 mimics. Photographs were taken immediately after wounding and 16 hr later. The results were quantified and
normalized to the mock transfected cells. (E) Transwell migration assays for mock transfected HCT116 cells and cells transfected with negative control
(AllStars Neg.), miR-941, or miR-1247 mimics. Representative fields of invasive cells on the membrane are shown. The bar graph represents the
average number of cells on the underside of the membranes in each treatment normalized to mock transfected cells.
doi:10.1371/journal.pone.0020628.g005
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[37]. For the HCT116 versus DKO comparison, Welch’s t test was
performed with a p-value cutoff of 0.05 and multiple testing
correction by false discovery rate (FDR). The microRNA array
data (GEO# GSE26819) can be accessed from the Gene
Expression Omnibus website.
Bisulfite sequencing
1 mg of genomic DNA from each sample was bisulfite converted
using the EpiTect kit (Qiagen, GmbH, Hilden) following
manufacturer’s protocol. PCR conditions and primer sequences
are provided in Table S3. The PCR amplicons were gel-purified
and subcloned into pCRII-TOPO vector (invitrogen, Carlsbad,
CA). At least eight clones were randomly selected and sequenced
on an ABI3730xl DNA analyzer to ascertain the methylation
patterns of each locus.
Detection of mature and primary miRNAs expression by
quantitative RT-PCR
Expression of mature miRNAs was determined using Quanti-
Tect SYBR Green RT-PCR kit (Qiagen, GmbH, Hilden) and was
normalized to endogenous U6 snoRNA expression using the
2
-DDCt method [38]. Briefly, 100 ng DNase-treated RNA from
each sample was added to 10 ml of the 26 SYBR green PCR
master mix, 0.2 ml RT-mix, 200 nM of each primer, and RNase-
free water to a total of 20 ml. For primary miRNA expression,
GAPDH was used as the normalization control. The expression of
each primary miRNA relative to GAPDH was also determined
using the 2
-DDCt method. The primer sequences for detecting
mature and primary miRNAs were designed as previously
described [23,39] and listed in Table S3. The mean of triplicate
experiments was graphed with standard deviations represented as
error bars.
Detection of putative host gene expression by
quantitative RT-PCR
Expression of putative host genes was determined using
QuantiTect SYBR Green RT-PCR kit (Qiagen, GmbH, Hilden)
and was normalized to GAPDH internally. The relative expression
after 5-aza-dC treatment was calculated using the 2
-DDCt method.
The RNA was extracted in the same manner as stated above. The
primer sequences are listed in Table S3. The mean of triplicate
experiments was graphed with standard deviations represented as
error bars.
Ectopic expression of miRNAs
Over-expression of miR-941, miR-1237, and miR-1247 in
HCT116, DKO, and DLD1 cells was achieved by transfecting the
cells with 20 nM miRNA duplexes that mimicked the mature
miR-941 (MSY0004984, Qiagen), miR-1237 (MSY0005592,
Qiagen), and miR-1247 (MSY0005899, Qiagen). The AllStars
Negative Control siRNA (1027281, Qiagen) was included as a
negative control. Transfections were carried out using Lipfecta-
mine
TM 2000 transfection reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer’s protocol. The transfection
efficiency was evaluated by transfection with the AF488 fluores-
cently labeled AllStars Negative Control (1027284, Qiagen).
Cell proliferation and viability assays
To assay for cell proliferation, at 24 hr post-transfection, cells
were re-plated at 8610
4 cells/well for HCT116 and DLD1 in 24-
well plates. At 96 hr after re-plating, 100 ml of CellTiter AQueous
(Promega, Madison, WI) was added to the cells for 1 hour, and the
absorbance was measured at 490 nm using a microplate reader
according to the manufacturer’s recommendations. At 48 and
96 hr after re-plating, cell numbers were counted using the trypan
blue dye exclusion method. The mean of triplicate measurements
was plotted with standard deviations represented as error bars.
DKO cells were plated on Day 0 at 4.6610
5 cells/well in 12-well
plates and transfected with miRNA mimic on Day 1. On Day 6
after plating, 100 ml of CellTiter AQueous (Promega, Madison,
WI) was added to the cells for 1 hour, and the absorbance was
measured at 490 nm using a microplate reader according to the
manufacturer’s recommendations. On Day 3 and Day 6 after
plating, cell numbers were counted using the trypan blue dye
exclusion method. The mean of triplicate measurements was
plotted with standard deviations represented as error bars.
BrdU incorporation assay
HCT116 cells transfected with miR-941 and miR-1247 mimics
and the AllStars Negative Control were re-plated on coverslips at
24 hr post-transfection. At 48 hr after re-plating, cells were
incubated with 10 mg/mL bromodeoxyuridine (BrdU) (Roche,
Indianapolis, IN) for 4 hr. The cells were then fixed in 4%
paraformaldehyde for 15 minutes, incubated with 2M HCl for 30
minutes to denature genomic DNA, and neutralized by 0.1M
Na2B4O7 for 5 minutes. The cells were subsequently stained with
mouse monoclonal anti-BrdU antibody (Roche, Indianapolis, IN)
and AF488 anti-mouse antibody (Invitrogen, San Diego, CA). The
cells were also stained with 4,6-diamidino-2-phenylindole (DAPI)
(Sigma, St Louis, MO). The percentage of BrdU incorporation
was determined by counting the number of BrdU-positive nuclei
among DAPI-stained nuclei in 4 independent microscope fields. A
minimum of 600 nuclei were counted for each experiment. The
mean of triplicate experiments was plotted with standard deviation
represented as error bars.
Wound-healing assay
Cells were plated in 24-well plates and grown to confluence.
The monolayer was wounded using the tip of a sterile 200 ml
pipette. Cell debris was removed by washing twice with serum-free
medium. Cells were then allowed to migrate into the denuded
areas for 16 hr. Photographs were taken immediately after
wounding (time 0 hr) and after 16 hr (time 16 hr) using the Leica
DMI3000 B inverted microscope. The results were quantified as a
percentage of the wound width closed by the cells at time 16 hr
(wound width at time 0 hr minus the wound width at time 16 hr)
divided by the wound width at time 0 hr. The experimental groups
were normalized to the results of the mock transfected cells. The
mean of six experiments was graphed with standard deviations
represented as error bars.
Migration assay
Transwell plates (24-well, 8-mm pore size, Costar, Corning, NY)
were used to conduct the migration assay. 5610
4 cells suspended
in McCoy’s 5A media containing 1% FBS were added to each
upper chamber while the lower chambers were filled with 500 ml
of McCoy’s 5A media containing 10% FBS. Cells were incubated
at 37uC with 5% CO2 for 6 hr to allow trans-well migration. At 6
hr, cells on the upper surface of the filters were removed using
cotton swabs. Cells that migrated to the lower surface of the filters
were rinsed with PBS, fixed in methanol, and stained with Giemsa
(Sigma, St Louis, MO). Photographs were taken using the Leica
DMI3000 B inverted microscope. The percentage change in
migration was determined by counting the numbers of cells that
migrated to the lower surface of the filters using ImageJ software
(Wayne Rasband, National institutes of Health, http://rsbweb.
Study of Epigenetically Regulated MicroRNAs
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separate microscopic fields were counted per membrane.
Statistical analysis
Results were expressed as means 6 standard deviation. Student
t test was used to determine the overall significance between data
points. A P-value of ,0.05 was considered significant.
Supporting Information
Figure S1 Additional bisulfite sequencing validation.
Bisulfite sequencing was carried out for (A) miR-193a, (B) miR-9-
3, and (C) miR-24-1 in parental HCT116 cells and DKO cells.
The UCSC genome browser screen capture shows the DNA
methylation signal in each sample. The rectangles mark the
regions validated by bisulfite sequencing. Each circle represents a
CpG dinucleotide. Black circles represent methylated cytosines
while white circles represent unmethylated cytosines.
(TIF)
Figure S2 Confirmation of miRNA microarray expres-
sion data by quantitative real-time RT-PCR analysis.
The fold changes in mature miRNA expression between DKO
and HCT116 cells as measured by real-time RT-PCR (light blue)
are compared to those measured by miRNA expression micro-
array (dark pink).
(TIF)
Figure S3 DNA methylation patterns at putative host
gene promoters. UCSC genome browser screen captures of the
promoter regions (61000 bp from annotated transcription start
site) for (A) RPS6KA4, putative host gene for miR-1237, (B) C9orf3,
putative host gene for miR-24-1 and miR-27b, (C) AB058779,
putative host gene for miR-602, (D) ANKRD30BL, putative host
gene for miR-663b, and (E) DNAJC5, putative host gene for miR-
941-1 and miR-941-3. The first track contains DNA methylation
at these promoters in HCT116, and the second track contains
DNA methylation in DKO cells as detected by MiGS.
(TIF)
Figure S4 Functional analysis of miR-941, miR-1237,
and miR-1247 in DLD1 cells. (A) Growth curves and (B) MTT
cell proliferation assays of mock transfected DLD1 cells and cells
transfected with non-coding negative control miRNA (AllStars
Neg.), miR-941, miR-1237, or miR-1247 mimics. (C) Wound-
healing assay for mock transfected HCT116 cells and cells
transfected with negative control (AllStars Neg.), miR-941, miR-
1237, or miR-1247 mimics. Photographs were taken immediately
after wounding and 16 hr later. The results were quantified and
normalized to the mock transfected cells.
(TIF)
Figure S5 Functional analysis of miR-941 and miR-1247
in DKO cells. (A) Growth curves and (B) MTT cell proliferation
assays of mock transfected DKO cells and DKO cells transfected
with non-coding negative control miRNA (AllStars Neg.), miR-
941, or miR-1247 mimics. (D) Transwell migration assays for
mock transfected DKO cells and cells transfected with negative
control (AllStars Neg.), miR-941, or miR-1247. Representative
fields of invasive cells on the membrane are shown. The bar graph
represents the average number of cells on the underside of the
membranes in each treatment normalized to mock transfected
cells.
(TIF)
Table S1 Summary of miRNAs methylated in HCT116 and
DKO cells.
(DOC)
Table S2 Methylation and expression data for miRNAs.
(DOC)
Table S3 List of PCR primers.
(DOC)
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